ERBB2 and ovarian cancer: Our data point to the conclusion that HER-2/neu peptides within ACE from HER-2/neu-overexpressing ovarian primary tumour cells are immunodominant and that such preparations can be used in the cellular adoptive immunotherapy of ovarian cancer.